



Nevada State Board of Pharmacy

Published to promote compliance of pharmacy and drug law

431 W Plumb Lane • Reno, NV 89509 • Phone: 775/850-1440 • Fax: 775/850-1444
<http://bop.nv.gov>

Board Members

Leo Basch, RPh, Las Vegas.....President
Kirk Wentworth, RPh, Carson City.....Treasurer
Jason Penrod, RPh, Reno.....Board Member
Kevin Desmond, RPh, Reno.....Board Member
Tallie Pederson, RPh, Las Vegas.....Board Member
Cheryl Blomstrom, Carson City.....Public Member

Newest Board Member

Nevada State Board of Pharmacy staff is delighted to welcome Jason Penrod, PharmD, RPh, as Governor Brian Sandoval’s newest appointment to the Board for a three-year term. Jason did his pre-pharmacy at University of Nevada, Reno, and is a graduate of Roseman University of Health Sciences College of Pharmacy (2005). He is currently employed as a pharmacist by Wal-Mart in northern Nevada, and brings a most interesting background that includes a widely decorated career as a UH-60 Black Hawk helicopter instructor pilot in the United States Army. A combat medical specialist, emergency medical technician, and medical officer-in-charge, Jason served in Afghanistan as a MEDEVAC pilot, and has been instrumental as pilot-in-command in several wildfire battles in both Nevada and northern California.

Jason began his pharmacy career as a pharmacy research technician in 2001; worked as a pharmacy technician in Reno, NV, for a bit; and then went on to pharmacy school. He even survived a stint in Executive Secretary Larry Pinson’s Boy Scout troop when he was in middle and high school, and is currently married to a pharmacist (Elizabeth) as well!

Congratulations, Jason! Having never worked with a pharmacy technician turned pharmacist who is also a combat helicopter flying, firefighting Board member, Board staff is most excited!

President Gandhi Leaving, Member Dalton Retiring

Sadly, the Board is losing its president, Kam Gandhi, to its neighbor state Arizona where Kam has been selected

as the next executive director of the Arizona State Board of Pharmacy. A longtime Las Vegas, NV resident, Kam is pulling up roots and heading further south, where he will reside in the Phoenix, AZ area. The Board wishes him the best, and hopes that the experiences he gained here in Nevada will serve Arizona well.

Board staff would also like to recognize Jack Dalton’s service to the Board; his term expired in October. Jack has been gracious enough to hang in there for the Board during the time necessary for the appointment of his replacement. Jack was a solid Board member, always willing and able, and will be missed.

Chart Order Versus Prescription

Requirements for Providing Pharmaceutical Products to Patients in Hospitals (NRS 639.0074), Skilled Nursing Facilities (NRS 449.0039), and Long-Term Care Facilities (NRS 449.0038)

It has been brought to the attention of Board staff that some hospitals are providing pharmaceutical services to hospital patients being discharged, and that some retail pharmacies are providing pharmaceutical services to long-term care facilities and/or skilled nursing facilities in violation of Nevada Revised Statutes (NRS) and Nevada Administrative Code (NAC).

A pharmacy serving a long-term care or skilled nursing facility cannot dispense a medication based on a chart order. The pharmacy can only dispense medication pursuant to a prescription from a licensed prescriber. A practitioner may prescribe a medication for a long-term care or skilled nursing patient via a written prescription with a “wet signature,” an electronic order, or an oral order. An oral order must be given to the pharmacist by the prescriber or his or her agent. An employee of a long-term care or skilled nursing facility is **not** an agent of the practitioner and therefore cannot verbally call in medication ordered via a chart order for a

Continued on page 4




Counterfeit Botox Found in the United States, FDA Warns

On April 16, 2015, Food and Drug Administration (FDA) alerted health care providers that a counterfeit version of Botox® was found in the United States and may have been sold to doctors' offices and clinics throughout the country. The counterfeit products may be identified by a missing lot number on the vial, missing information on the carton (next to LOT, MFG, and EXP), and a displayed active ingredient as "Botulinum Toxin Type A" instead of "OnabotulinumtoxinA." The counterfeit products were sold by an unlicensed supplier who is not authorized to ship or distribute drug products in the US, according to an FDA Drug Safety Alert. The agency advises health care providers to confirm that the distributor from which they purchase Botox is authorized by Allergan, the drug's manufacturer. No adverse events related to this product have been reported to FDA.

Medical practices that purchase and administer counterfeit, illegal, and unapproved medications from unlicensed or foreign sources are putting patients' health at risk, as patients may not be getting proper treatment, warns FDA. Wholesale drug distributors must be licensed in the states where they conduct business. Suspicious Botox products may be reported to FDA's Office of Criminal Investigations. More information is available on the FDA website at www.fda.gov/Drugs/DrugSafety/ucm443217.htm.

One way pharmacies can be assured of the legitimacy of a wholesale distributor is to look for the National Association of Boards of Pharmacy® (NABP®) Verified-Accredited Wholesale Distributors® (VAWD®) Seal. Wholesale distributors that achieve VAWD accreditation are in compliance with state and federal laws, as well as NABP's VAWD criteria. Wholesale distributors that display the VAWD Seal as part of their accreditation have undergone a criteria compliance review, including a rigorous review of their operating policies and procedures, licensure verification, survey of facility and operations, background checks, and screening through the NABP Clearinghouse. Accredited facilities are reviewed annually and undergo an on-site survey every three years. Created in 2004, the accreditation program plays a pivotal role in preventing counterfeit drugs from entering the US drug supply.

Seven Persistent Safety Gaffes in Community/Ambulatory Settings That Need to Be Resolved!

 This column was prepared by the Institute for Safe Medication Practices (ISMP). ISMP is an independent nonprofit agency and federally certified patient safety organization that analyzes medication errors, near misses, and potentially hazardous conditions as reported by pharmacists and other practitioners. ISMP then makes appropriate contacts with companies and regulators, gathers expert opinion about prevention measures, and publishes its recommendations. To read about the risk reduction strategies that you can put into practice today, subscribe to ISMP Medication Safety Alert!® Community/Ambulatory Care Edition by visiting www.ismp.org. ISMP provides legal protection and confidentiality for submitted patient safety data and error reports. Help others by reporting actual and potential medication errors to the ISMP National Medication Errors Reporting Program Report online at www.ismp.org. Email: ismpinfo@ismp.org.

ISMP has been reflecting on the strength and resolve of many across the nation who have demonstrated an unparalleled commitment to keeping patients safe. Despite the many safety accomplishments in 2014, ISMP cannot help but mull over persistent medication safety gaffes that continue to be unresolved. ISMP would like to share seven persistent safety gaffes of 2014, in three parts, with NABP *National Pharmacy Compliance News* readers with the hope that they will join ISMP in bringing attention to these crucial issues and the compelling need for their resolution. Part one of the three-part series is below.

1) Patient Counseling: Still Only a Veiled "Offer" in Many States

The effectiveness of patient counseling in a community pharmacy to detect and prevent medication errors, and its link to improved medication adherence and positive clinical outcomes have been well documented in the literature. Yet, studies have placed patient counseling rates at only eight percent to 42%. An increase in the frequency and quality of patient counseling has been linked to state-specific regulations that require patient counseling for new prescriptions coupled with strict enforcement surveillance. States that require an "offer" to counsel have very low patient counseling rates. Patients often fail to recognize an offer to counsel when simply asked, "Do you have any questions?" or told to "Please sign here." They may not even know what to ask. This means that, with few exceptions, pharmacies in states that require only an offer to counsel will likely dispense a powerful opioid such as fentanyl transdermal patches and allow the patient or caregiver to walk out of the pharmacy without even a brief discussion about safe use and disposal. ISMP has long promoted mandatory patient counseling in community pharmacies for prescriptions for targeted high-alert medications.

For a list of high alert community medications, please visit www.ismp.org/communityRx/tools/ambulatoryhighalert.asp. ISMP hopes you will use this list to determine which medications require mandatory patient education in order to reduce the risk of errors and minimize harm.

2) Patients Impacted by Dispensing Errors: Callous Response From Pharmacists

When patients report dispensing errors to ISMP, they are usually more upset about the response they received when contacting the pharmacist or pharmacy manager than the actual error itself. All too often, consumers tell ISMP that pharmacy staff have responded in a callous manner when confronted with the possibility of a dispensing error, demonstrating a lack of empathy and concern for the adverse effects the patient might have experienced. While pharmacy staff may want to be more responsive to patients who report errors, they are often following corporate policies that are focused on legal concerns. As patients are continually encouraged to be active participants in their health care, they want and deserve honest disclosure of errors, and knowledge that there is an action plan to reduce the risk of it happening again.

Flurbiprofen-Containing Topical Medication May Be Dangerous to Pets, Cautions FDA

People who use topical medications containing flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), should take care to prevent their pets from being exposed to the drug, recommended FDA in an April 2015 Safety Alert. The warning is in response to reports of cats in two separate households that became ill or died after their owners used topical medications containing flurbiprofen to treat



muscle, joint, or other pain. Two cats in one household developed kidney failure and recovered with veterinary care. Two cats in a second household developed symptoms that included reluctance to eat, lethargy, vomiting, melena, anemia, and dilute urine, and subsequently died despite veterinary care. A third cat in the second household also died after the owner stopped using the medication. Necropsies on the three cats found evidence that were consistent with NSAID toxicity. The pet owners had applied the drug to their own neck or feet, and not directly to the pet, and it is not known exactly how the cats became exposed to the medication, the Safety Alert notes.

Health care providers who prescribe or dispense topical pain medications containing flurbiprofen should advise patients with pets to take steps to prevent exposure of the pets to the medication. Additional information is available in the FDA Safety Alert available at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm443386.htm.

New FDA Drug Info Rounds Videos Available

FDA Drug Info Rounds, a series of online videos, provides important and timely drug information to practicing clinical and community pharmacists so they can help patients make better decisions. The latest Drug Info Rounds videos are as follows.

- ◆ In “NDC Directory,” pharmacists demonstrate how to use this quick, easy, online resource.
- ◆ In “FAERS,” pharmacists discuss the FDA Adverse Event Reporting System (FAERS) and review three ways FAERS data is made available to the public.

Drug Info Rounds is developed with contributions from pharmacists in FDA’s Center for Drug Evaluation and Research, Office of Communications, Division of Drug Information. These videos and previous Drug Info Rounds resources are available on the FDA website at www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm211957.htm.

Mucinex Cold, Sinus, and Flu Medications Recalled Due to Possible Labeling Error

In April 2015, RB (formerly Reckitt Benckiser) of Parsippany, NJ, issued a voluntary recall of certain lots of liquid Mucinex® due to a potential error involving the over-the-counter medications’ drug facts labels. While the front label of the recalled lots correctly lists the name of the product as well as the active ingredients, some bottles may not have the correct corresponding drug facts label on the back. The recall was initiated after a confirmed report from a retailer. The recalled medications include:

- ◆ MUCINEX FAST-MAX Night-Time Cold & Flu;
- ◆ MUCINEX FAST-MAX Cold & Sinus;
- ◆ MUCINEX FAST-MAX Severe Congestion & Cough; and
- ◆ MUCINEX FAST-MAX Cold, Flu & Sore Throat.

If mislabeled, consumers who purchase these products may be unaware of the side effects and potential risks associated with active ingredients such as acetaminophen, dextromethorphan, guaifenesin, phenylephrine, and/or diphenhydramine. RB is recalling these products as a precautionary measure to ensure consumers have all relevant facts and warnings; the company asks consumers to dispose of any unused product.

Additional information about the recall, including the lot numbers and expiration dates for the recalled medications and guidelines for

safe disposal, is available on the FDA website at www.fda.gov/Safety/Recalls/ucm444028.htm.

Pharmacists Are Performing More Patient Care Activities, National Survey Indicates

Pharmacists are performing more patient care activities in a variety of health care settings and are spending less time in traditional dispensing roles, indicates the *2014 National Pharmacist Workforce Survey*. Specifically, the report found that 60% of pharmacists provided medication therapy management, and 53% performed immunizations in 2014, indicates a press release from the American Association of Colleges of Pharmacy (AAPC). The survey was created using a random sample of 5,200 individuals selected from a list of 7,000 licensed pharmacists in the US. Response rate to the survey was 48%.

Additional details, including the full results of the survey and an executive summary, are available through the Resources section of the AAPC website, www.aacp.org.

Potentially Lethal Drug Sold Globally as Diet Supplement, Warns INTERPOL

INTERPOL has issued a global alert for a drug known as 2,4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as a dieting and body building aid. The “Orange Notice” warning about DNP was published in May 2015, following the death of a woman in the United Kingdom and the serious illness of a man in France. In the 1930s, DNP was used to boost metabolism and encourage weight loss, but it was taken out of circulation due to several deaths. Sold as a plain yellow powder, capsules, or cream, DNP is often illegally manufactured and sold via the Internet; unsafe manufacturing of the drug and potential contamination may be magnifying the dangers of taking the drug, notes INTERPOL.

Additional information is available on the INTERPOL website at www.interpol.int/News-and-media/News/2015/N2015-050.

HHS Announces New Interactive Training on Safe Opioid Use

The Department of Health and Human Services (HHS) has announced a new, interactive training course that teaches health care providers how to talk to patients about safely using opioids to manage chronic pain. The course, “Pathways to Safer Opioid Use,” also teaches implementation strategies for meeting the opioid-related recommendations from the National Action Plan for Adverse Drug Event Prevention. Adverse drug events (ADEs) are the largest contributor to hospital-related complications and account for more than 3.5 million physician office visits each year, according to HHS. The training, which is offered at no cost, includes self-guided interactive videos with decision points to help users learn how to apply health literacy strategies to help patients understand and act on information to prevent opioid-related ADEs; identify individual risk factors, opioid medications, and interactions that place individuals with chronic pain at increased risk for opioid-related ADEs; recognize the importance of a multidisciplinary team-based approach to treating patients with chronic pain; and demonstrate the ability to combine the principles of the Health Literate Care Model and the biopsychosocial model.

Additional information, including a link to the National Action Plan for Adverse Drug Event Prevention, is available on the course website at <http://health.gov/hcq/training.asp#pathways>.

Continued from page 1

patient. The order must be communicated to the pharmacy servicing the facility by the practitioner or his or her agent.

The authority for a pharmacy to provide medication via prescription from a licensed practitioner to a long-term care or skilled nursing home patient (or hospital without a pharmacy on premises) is contingent on a licensed practitioner providing a legal prescription for a specific patient in the facility to the pharmacy providing services to that facility. The authority for a long-term care or skilled nursing facility to administer medication to the patient in the medical facility is given via a chart order.

An institutional pharmacy within a hospital can only dispense medications to a patient via a chart order that is signed by the practitioner within 48 hours. A hospital pharmacy cannot dispense a medication via a prescription written by a practitioner for a patient being discharged. A chart order containing the medications with which the patient is to be discharged cannot be used as authorization to dispense the medications to the patient being discharged. The authority to dispense via chart order to an inpatient is limited to medical facilities. A practitioner may prescribe medication for a patient discharged from a hospital, but the prescription order to dispense the medication must be filled by a pharmacy or other entity that has the legal authority under NRS and/or NAC to dispense the medication via a prescription. To provide any discharge medications to a patient, a hospital must have a separate retail licensed pharmacy with a separate inventory, and a prescription that complies with NRS 639.2353.

Failure to comply with NRS or NAC is grounds for discipline.

- ◆ **NRS 454.0041, NRS 639.004, and NAC 639.442: “Chart order” defined.**
- ◆ **NRS 639.013: “Prescription” defined.**
- ◆ **NRS 639.0085: “Institutional pharmacy” defined.**
- ◆ **NRS 639.23275: Delivery of a controlled substance or dangerous drug to hospital, facility for intermediate**

care, or facility for skilled nursing that does not have pharmacy on premises.

- ◆ **NRS 449.0151: “Medical facility” defined.**
- ◆ **NRS 449.0039: “Facility for skilled nursing” defined.**
- ◆ **NRS 449.0038: “Facility for intermediate care” defined.**
- ◆ **NRS 639.2352: Transmission of prescription to pharmacist; contents of written prescription; specific directions for use; requirements for written prescription; and authentication of prescription given by electronic transmission.**

2015: Year of the Pharmacist . . . Renewal, That Is!

As this *Newsletter* finds you, Board staff will avidly be preparing for another season of license renewals. Please be on the lookout for your renewal form around mid-September, on which your login information will be provided. An on time renewal costs \$180 for the biennium. If you choose not to renew online with a credit card, then it is strongly suggested to submit your form and a money order with enough time for staff to process. By postmarking your form by October 31, 2015, you will avoid the additional \$140 late fee; however, you will not have a license to work on November 1. A paper renewal can take two to three weeks (including mail time) to reflect renewal and receive documentation in hand, while renewing online is instant. Please refer to the Board website’s Renewal of a License page as we approach this momentous season!

Page 4 – July 2015

The *Nevada State Board of Pharmacy News* is published by the Nevada State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation™ (NABPF™) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Larry Pinson, PharmD - State News Editor
Carmen A. Catizone, MS, RPh, DPh - National News Editor
& Executive Editor
Deborah Zak - Communications Manager